ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 905

Regenerating Cartilage and Reversing Osteoarthritis (OA) Stimulation of Adenosine A2A Receptors (A2AR) Increases Cartilage Volume and Matrix in Vitro and In Vivo

Carmen Corciulo1, Cristina Castro2, Thomas Coughlin3, Tuere Wilder1, Oran Kennedy4 and Bruce Cronstein5, 1Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 2Medicine, NYU School of Medicine, New York, NY, 3Orthopaedic Surgery, NYU School of Medicine, New York, NY, 4Department of Anatomy, Royal College of Surgeons, Dublin, Ireland, 5Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Adenosine receptors, cartilage, chondrocytes, osteoarthritis and therapeutic targeting

Session Information

Date: Sunday, November 5, 2017

Title: Biology and Pathology of Bone and Joint

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: We have recently reported that endogenously produced adenosine, interacting with A2AR, is a critical autocrine factor for maintenance of chondrocyte and cartilage homeostasis and intra-articular injections of liposomal preparations of adenosine inhibit progression of OA in a post-traumatic OA (PTOA) model in rats. We therefore determined whether intra-articular injection of a more selective A2AR agonist could also prevent progression and possibly reverse OA in this model and in the obesity related OA model in mice.

Methods:

PTOA was induced in SD rats following rupture of the anterior cruciate ligament (ACL) by application of external force to the knee. Starting 4 weeks after injury, when OA has already progressed, knees were injected with 100ul of saline, empty liposomes (LIPO) or liposomes containing CGS21680 (LIPO-CGS) every 10 days (6 injections) before sacrifice. The cartilage volume in OA and normal knees was measured by microCT after staining with hexabrix (40%). Chondrocytes were isolated from neonatal mice and cultured, only first passage chondrocytes were studied.

For the obesity-OA model, C57Bl6 mice (3/group, 12 weeks old) were fed a 60% fat diet (HFF mice). After 3 months, when OA was present, mice received intrarticular knee injection (10 µl) of LIPO, LIPO-CGS or liposomal adenosine (LIPO-Ado) every 10 days for 4 injections before sacrifice.

Results: Injection of LIPO-CGS but not saline or LIPO, significantly reduced swelling of affected rat knees (p<0.001). Surprisingly, there was an increase in tibial and femoral cartilage volume in normal knees treated with intra-articular injections of LIPO-CGS but not LIPO or saline (47% increase in tibia and 22% in femur). More importantly, intra-articular injections of LIPO-CGS, but not LIPO or saline, increased tibial and femoral cartilage volume in OA knees, as compared to normal knees and completely abrogated the histologic evidence of OA as well (OARSI score for CGS21680 0.66±0.33 vs 4.55±0.82 in the vehicle group and 3.90±0.89 in the saline group). There was marked chondrocyte proliferation in the deep cartilage of knees of rats treated with LIPO-CGS (Ki67 immunofluorescence).

Similarly, LIPO-CGS reversed the OA changes in the obesity related OA model. HFF mice had an OARSI score of 4.7±1.2. Treatments with LIPO-Ado and lipo-CGS decreased OA severity (OARSI score 1.3±0.3 and 0.7±0.6, respectively, p<0.001 vs untreated). A2AR stimulation increased TGF-β immunostaining in LIPO-CGS-injected joints and increased TGF-b production by cultured neonatal murine chondrocytes with increased SMAD2/3 phosphorylation and diminished RUNX2 expression.

Conclusion: These results demonstrate that intra-articular injection of a long-acting A2AR agonist stimulates chondrocyte and cartilage regeneration, likely by a TGF-β-dependent mechanism. More importantly, these results indicate that treatment with an A2AR agonist can reverse OA in both traumatic and obesity-related OA.


Disclosure: C. Corciulo, None; C. Castro, None; T. Coughlin, None; T. Wilder, None; O. Kennedy, None; B. Cronstein, NIH grant, 2,Athritis foundation grant, 2,AstraZeneca, 2,Celgene, 2,Eli Lilly & Co., 5,AstraZeneca, 5,Canfite Biopharma, 1.

To cite this abstract in AMA style:

Corciulo C, Castro C, Coughlin T, Wilder T, Kennedy O, Cronstein B. Regenerating Cartilage and Reversing Osteoarthritis (OA) Stimulation of Adenosine A2A Receptors (A2AR) Increases Cartilage Volume and Matrix in Vitro and In Vivo [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/regenerating-cartilage-and-reversing-osteoarthritis-oa-stimulation-of-adenosine-a2a-receptors-a2ar-increases-cartilage-volume-and-matrix-in-vitro-and-in-vivo/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regenerating-cartilage-and-reversing-osteoarthritis-oa-stimulation-of-adenosine-a2a-receptors-a2ar-increases-cartilage-volume-and-matrix-in-vitro-and-in-vivo/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology